These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Functionalizing cell-based therapy for age-related macular degeneration. Zarbin MA Am J Ophthalmol; 2007 Apr; 143(4):681-2. PubMed ID: 17386276 [No Abstract] [Full Text] [Related]
5. NICE delays decision on drugs for macular degeneration. White C BMJ; 2007 Aug; 335(7615):319. PubMed ID: 17703016 [No Abstract] [Full Text] [Related]
6. Rinsing of the cannula prior to intravitreal injection. Degenring RF; Jonas JB Arch Ophthalmol; 2004 Oct; 122(10):1571-2; author reply 1572. PubMed ID: 15477484 [No Abstract] [Full Text] [Related]
7. Drugs for some common eye disorders. Treat Guidel Med Lett; 2007 Jan; 5(53):1-8. PubMed ID: 17179899 [No Abstract] [Full Text] [Related]
8. [Bevacizumab versus ranibizumab: a draw?]. Souied EH; Cohen SY; Kodjikian L J Fr Ophtalmol; 2012 Feb; 35(2):79-81. PubMed ID: 22033297 [No Abstract] [Full Text] [Related]
9. Treatment for wet macular degeneration. FDA Consum; 2006; 40(5):6. PubMed ID: 17326303 [No Abstract] [Full Text] [Related]
10. Sight-saving treatments for age-related macular degeneration. New drugs offer new hope for managing a leading cause of blindness. Johns Hopkins Med Lett Health After 50; 2012; 24(12):1-4. PubMed ID: 23757782 [No Abstract] [Full Text] [Related]
11. Avastin and Lucentis are equally effective in treating AMD. Optom Vis Sci; 2011 Jul; 88(7):E895-6. PubMed ID: 21709531 [No Abstract] [Full Text] [Related]
13. Regulatory aspects of drug approval for macular degeneration. Gryziewicz L Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706 [TBL] [Abstract][Full Text] [Related]
14. Balancing the risks and benefits in AMD. Beaumont PE; Kang HK Clin Exp Ophthalmol; 2005 Feb; 33(1):108-10; author reply 110-1. PubMed ID: 15670095 [No Abstract] [Full Text] [Related]
15. [Future methods of treatment in age related macular degeneration]. Turlea C Oftalmologia; 2012; 56(1):30-5. PubMed ID: 22888684 [TBL] [Abstract][Full Text] [Related]
16. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Curtis LH; Hammill BG; Schulman KA; Cousins SW Arch Ophthalmol; 2010 Oct; 128(10):1273-9. PubMed ID: 20937996 [TBL] [Abstract][Full Text] [Related]
19. Pilot study of safety and effect of combined intravitreal bevacizumab and methotrexate for neovascular age-related macular degeneration. Soheilian M; Movaseghi M; Ramezani A; Peyman GA Eur J Ophthalmol; 2011; 21(1):77-82. PubMed ID: 20872362 [TBL] [Abstract][Full Text] [Related]